Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney Diseases

- 3 Zhihang Su¹, Qijun Wan¹*
- ⁴ ¹Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of
- 5 Shenzhen University, Shenzhen, China

6 * Correspondence:

- 7 Qijun Wan (Email: <u>yiyuan2224@sina.com</u>)
- 8
- 9 Word Count:
- 10 Abstract: 328 words
- 11 Text (excluding references): 3120 words

12 Keywords: Membranous nephropathy, Mendelian randomization, druggable genes,

13 Therapeutic targets, genome-wide association study (GWAS).

14 Abstract

- 15 Background:
- 16 Kidney diseases, including membranous nephropathy (MN), IgA nephropathy (IgAN), and chronic
- 17 kidney disease (CKD), pose significant global health challenges due to their high prevalence and

18 severe outcomes. There is still an urgent need to discover new targets for treating kidney diseases.

- 19 Mendelian randomization (MR) has been widely used to repurpose licensed drugs and discover novel
- 20 therapeutic targets. Thus, we aimed to identify novel therapeutic targets for Kidney diseases and
- 21 analyze their pathophysiological mechanisms and potential side effects.
- 22 Methods:
- 23 Integrated with currently available druggable genes, Summary-data-based MR (SMR) analysis was
- 24 conducted to estimate the causal effects of blood expression quantitative trait loci (eQTLs) on kidney
- diseases. A study was replicated using distinct blood eQTL and diseases genome-wide association
- study (GWAS) data sources to validate the identified genes. The eQTL data was obtained from
- eQTLGen and GTEx v8.0, with sample sizes of 31,684 and 15,201, respectively. The data on kidney
- diseases was sourced from the Kiryluk Lab, CKDgen, and the Finngen consortium, with sample sizes
- ranging from 7,979 to 412,181. Subsequently, reverse two-sample MR and colocalization analysis
- 30 were employed for further validation. Finally, the potential side effects of the identified key genes in
- 31 treating kidney diseases were assessed using phenome-wide MR and mediation MR.
- 32 Results:
- 33 After correcting for the false discovery rate, a total of 20, 23, and 6 unique potential genes were
- 34 found to have causal relationships with MN, IgAN, and CKD, respectively. Among them, MN
- 35 showed validated associations with one gene (HCG18), IgAN demonstrated associations with four

36 genes (AFF3, CYP21A2, DPH3, HLA-DRB5), and chronic kidney disease (CKD) displayed an

37 association with one gene (HLA-DQB1-AS1). Several of these key genes are druggable genes.

38 Further phenome-wide MR analysis revealed that certain genes may be associated with diabetes, fat

39 metabolism, and infectious diseases, suggesting that these factors could potentially serve as

- 40 mediators.
- 41 Conclusions:

42 This study presents genetic evidence that supports the potential therapeutic benefits of targeting these

43 key genes for treating kidney diseases. This is significant in prioritizing the development of drugs for

44 kidney diseases.

45 **1** Introduction

46 Kidney diseases, including membranous nephropathy (MN), IgA nephropathy (IgAN), and chronic

47 kidney disease (CKD), pose significant global health challenges due to their high prevalence and

48 severe outcomes. MN, characterized by the deposition of immune complexes in the glomerular

49 basement membrane, often leads to nephrotic syndrome and progressive renal failure if untreated(1).

- 50 IgAN, the most common glomerulonephritis worldwide, is marked by the accumulation of IgA in the
- glomeruli, causing inflammation and potentially advancing to end-stage renal disease (ESRD)(2).
 CKD, defined by the gradual loss of kidney function over time, affects millions and significantly
- 52 CKD, defined by the gradual loss of kidney function over time, affects minons and significantly 53 increases the risk of cardiovascular disease and mortality(3). Despite advancements in understanding
- 54 the pathophysiology of these diseases, effective treatments remain limited. Current therapeutic
- 55 strategies primarily focus on managing symptoms and slowing disease progression, but they do not

56 halt or reverse kidney damage. For instance, the treatment of MN and IgAN often involves

- 57 immunosuppressive therapies, which can have substantial side effects and variable efficacy.
- 58 Similarly, CKD management revolves around controlling hypertension and diabetes, delaying
- 59 progression rather than curing the disease. The identification of novel therapeutic targets is crucial to
- 60 developing more effective treatments. With advances in genomics, proteomics, and bioinformatics,

61 there is an unprecedented opportunity to uncover molecular pathways involved in kidney disease

62 pathogenesis. Targeting these pathways could lead to innovative therapies that address the underlying

63 causes of kidney damage rather than merely alleviating symptoms. This approach holds promise for

- 64 improving patient outcomes and quality of life, highlighting the importance of ongoing research in
- 65 this field.

66 Mendelian randomization (MR) is a powerful epidemiological method that leverages genetic variants

67 as instrumental variables to assess the causal effects of modifiable risk factors on disease

68 outcomes(4). By utilizing the random assortment of genes from parents to offspring, MR mimics the

69 conditions of a randomized controlled trial, thereby minimizing confounding and reverse causation

70 issues that often plague observational studies(5,6). This technique has gained prominence in

71 identifying potential drug targets by providing insights into the causal relationships between

72 biomarkers, risk factors, and disease outcomes(7,8).

73 In recent years, MR has been increasingly applied to drug discovery and development. By correlating

74 genetic variants that influence drug target genes with clinical outcomes, MR can validate the

therapeutic potential of specific targets before costly clinical trials are initiated. For instance, the use

- of MR has facilitated the identification of novel therapeutic targets for cardiovascular diseases by
- confirming the causal role of lipid levels and inflammatory markers in disease progression(9,10).

- 78 Similarly, MR studies have highlighted the potential of targeting specific metabolic pathways in
- 79 treating diabetes and other metabolic disorders(11,12).
- 80 The application of MR in drug target discovery is not without challenges, including the need for
- 81 robust genetic instruments and comprehensive datasets. However, integrating MR with advanced
- 82 genomic technologies and large-scale biobanks holds great promise for the future of precision
- 83 medicine. By enhancing our ability to identify and validate causal relationships between potential
- 84 drug targets and disease outcomes, MR can accelerate the development of effective and safe
- 85 therapeutics, ultimately improving patient care.

86 2 Methods

- 87 This study was conducted according to the reporting guidelines outlined by the Strengthening the
- 88 Reporting of Observational Studies in Epidemiology (STROBE) initiative.

89 2.1 Identification of druggable genes

- 90 The information regarding druggable genes was obtained from the Drug-Gene Interaction Database
- 91 (DGIdb V.5.0.6) and the latest review on the "druggability" of genes(13). DGIdb provides
- 92 comprehensive information on drug-gene interactions and druggable genes from various sources,
- 93 including publications, databases, and other web resources(14). For this study, we retrieved the
- 94 "categories" data from DGIdb, which was released in February 2022. This dataset contains a
- 95 comprehensive list of druggable genes mapped to Entrez genes in DGIdb. Furthermore, we 96 supplemented our findings with additional gene listings of druggable genes from the review
- 96 supplemented our findings with additional gene listings of druggable genes from the review 97 conducted by Finan et al.
- 97 conducted by Finan et al.

98 2.2 Expression quantitative trait loci

- The blood eQTL dataset used in this study was obtained from eQTLGen (https://eqtlgen.org/). The dataset comprises blood samples from 31,684 individuals of European ancestry who were in good health(15). It covers cis-eQTLs of 16,987 genes. We exclusively considered cis-eQTL results that exhibited high significance (false discovery rate (FDR) < 0.05) and also incorporated allele frequency information. We identified genetic variants located within a 1000 kb range on both sides of the coding sequences (cis) that exhibited a strong association with gene expression. These variants were extracted using eQTL summary statistics obtained from the eQTLGen Consortium. Nonetheless, it
- should be noted that eQTLGen does not encompass variants linked to gene expression levels on the
- 107 X and Y chromosomes, as well as mtDNA. Further details regarding the data can be found in the
- 108 original publication. Additionally, to validate the obtained results, we employed the whole-blood cis-
- 109 eQTL data from the Genotype-Tissue Expression (GTEx) project, specifically GTEx V.8
- 110 (https://gtexportal.org/home/datasets), which consisted of 15,201 samples.

111 2.3 Kidney diseases data

- 112 The primary source of discovery data for this study is the MN and IgAN databases provided by the
- 113 Kiryluk Lab(16,17), along with the CKD database provided by the Finngen Consortium. To validate
- our findings, we additionally utilized the databases from the Finngen Consortium, CKDgen, and
- 115 other sources. Regarding the Kiryluk Lab data, all MN cases were diagnosed utilizing the gold
- standard method of renal biopsy, whereas all IgAN cases were defined through dominant mesangial
- 117 IgA staining on renal biopsy immunofluorescence. Cases potentially associated with secondary
- 118 causes (e.g., Hepatitis, autoimmune, or malignant diseases) were excluded to uphold study rigor.

119 CKDgen's research covers chronic kidney disease (CKD), which is defined by the criteria of

 $120 \qquad eGFRcrea < 60 \ ml/min/1.73 m^2 \ and \ includes \ conditions \ such \ as \ urinary \ albumin-to-creatinine \ ratio$

121 (UACR > 30 mg/g) and gout(18,19). As the study samples are predominantly sourced from the

122 general population, the research did not primarily focus on severe CKD and severe proteinuria. The

- 123 analysis concentrates on cases with $eGFR > 15 \text{ ml/min}/1.73\text{m}^2$ and excludes patients receiving
- 124 dialysis treatment.

125 **2.4 Mendelian randomization**

126 The MR method necessitates the fulfillment of three fundamental assumptions. To broaden the 127 scope of MR, we performed a summary-data-based MR approach that estimates pleiotropic 128 associations between genetic determinants of traits (e.g., gene expression, DNA methylation, or 129 protein abundance as exposures) and our target complex traits, including MN, IgAN, and CKD. The 130 heterogeneity-independent instruments (HEIDI) test is one of the sensitivity analysis techniques 131 utilizing an external reference to estimate linkage disequilibrium (LD). Following false discovery rate 132 (FDR) correction, genes exhibiting SMR < 0.05 and HEIDI test > 0.05 are deemed to possess causal 133 relationships. Furthermore, we examine the observed effect sizes (OR values) to discern their roles as 134 risk or protective factors. Subsequent to the completion of the SMR analysis, we conducted 135 additional sensitivity analysis employing the Two-sample MR (TSMR) approach, encompassing 136 inverse variance weighted (IVW) and the Wald ratio. Each method relies on distinct assumptions 137 regarding the validity of instrumental variables to compute estimates of causal effects, thus 138 furnishing robust evidence for our findings. In conducting TSMR, we employ data from the 1000 139 Genomes project (HG19/GRCh37) as a substitute in cases where effect allele frequency data is

140 missing.

141 **2.5 Phenome-wide MR and mediation MR**

142 Using data from the UK Biobank as the outcome and key genes as the exposure, we employed

143 phenome-wide Mendelian randomization (MR) to identify phenotypes associated with the key genes,

144 potentially indicating comorbidity relationships with kidney diseases. Moreover, to identify

145 intermediary factors associated with kidney diseases, we conducted two-sample MR analysis using

146 key genes as the exposure, UK Biobank data as the mediator, and kidney diseases as the outcome.

147 **2.6 Bayesian colocalization analysis**

Occasionally, a single nucleotide polymorphism (SNP) may be situated within multiple gene regions. 148 149 In such instances, if the SNP contains information on the expression of quantitative trait loci (QTL) 150 for two or more distinct genes, its influence on kidney diseases (MN, IgAN, and CKD) will reflect a 151 combination of various genes. Co-localization analysis is employed to validate the presence of shared 152 causal genetic variations between kidney diseases and eOTL. Briefly, we conducted the colocalization analysis to investigate the co-localization of kidney disease risk and SNP within ± 100 153 kb of the transcription start site (TSS) of each gene in eQTL, focusing on significant MR (Mendelian 154 randomization) results from the discovery phase (P1 = 1×10^{-5} , P2 = 1×10^{-5} , and P12 = 1×10^{-5}). P1 155 denotes the probability of a significant eQTL association with the provided SNP, P2 signifies the 156 157 probability of the given SNP being associated with kidney disease, and P12 indicates the probability 158 of the given SNP being associated with both kidney disease and eQTL outcomes. The researchers evaluated five hypotheses, and posterior probabilities (PP) are utilized to quantify the level of support 159 160 for each hypothesis, categorized as PPH0 to PPH4, with a specific emphasis on PPH3 and PPH4. 161 PPH3 represents the co-localization of gene expression and kidney disease, demonstrating distinct

162 causal variations within the same gene locus, whereas PPH4 indicates the co-localization of gene

163 expression and kidney disease, manifesting shared causal variations. Due to the limited power of co-

localization analysis, we confined our analysis to genes that surpassed a threshold of PPH3+PPH4 \geq

165 0.5 (0.5 to 0.8 indicating moderate strength, >0.8 indicating high strength).

166 2.7 Functional Enrichment Analysis

167 The functions of genes and potential signaling pathways associated with tumorigenesis and 168 progression in kidney diseases were explored using the Metascape database (v3.5.20240101). By utilizing these selected functional sets in Metascape, our aim was to gain insights into the molecular 169 170 functions, biological processes, pathways, and structural complexes associated with the genes in our 171 dataset. Additionally, the Signature Module sets enabled us to explore cellular signatures associated 172 with cell types, chemical and genetic perturbations, immunological signatures, and oncogenic 173 signatures. The Miscellaneous sets provided information on transcription factor targets and gene-174 disease associations sourced from trusted databases, including TRRUST, PaGenBase, and 175 DisGeNET. Furthermore, the L1000 sets allowed us to examine the effects of genetic perturbations, 176 compounds, cDNA, and ligands. Lastly, we explored the vaccine response signatures, with a 177 particular focus on COVID-related signatures, to gain insights into the immune response associated 178 with our target genes. Through this comprehensive analysis, our aim was to uncover potential 179 functional mechanisms, pathways, and interactions relevant to our target of interest. Gene Ontology 180 (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were 181 conducted. All genes that exhibited significant alterations after correction were included in this 182 analysis. The GO analysis was categorized into three sections: BP (biological process), CC (cellular component), and MF (molecular function). A P-value below 0.05 was considered statistically 183

184 significant.

185 **3 Results**

186 We successfully identified multiple causal associations between gene expression and kidney diseases 187 in the blood through SMR tests. To control for type I errors across the entire genome, we conducted 188 false discovery rate (FDR) correction, which revealed robust evidence of associations (FDR < 0.05). 189 Subsequently, we performed HEIDI tests (P > 0.05) to explore whether these associations resulted 190 from shared causal variants rather than pleiotropy. To support our findings, we conducted sensitivity 191 analyses using other MR methods that are based on similar assumptions, demonstrating consistent 192 outcomes. Additionally, to address confounding factors, we conducted a colocalization analysis, 193 which assessed the posterior probability of shared causal variation (PPH4) between gene expression 194 and kidney diseases, employing a threshold of >0.50. Additionally, we replicated our findings by 195 performing additional analyses utilizing other GWAS studies. The identified genes were classified 196 into four distinct target groups based on SMR, TSMR, colocalization analysis, and external

- 197 replication results.
- 198 Genes with an FDR-corrected SMR-P value < 0.05 and a HEIDI test result > 0.05 were considered 199 essential criteria and classified as tier 1 targets when supported by TSMR, colocalization, and 200 replication. Genes supported by any two of TSMR, colocalization, and replication were classified as 201 tier 2 targets. Genes supported by any one of TSMR, colocalization, or replication were classified as
- 201 ther 2 targets. Genes supported by any one of 15MR, colocalization, of replica 202 tier 3 targets. The remaining genes were classified as tier 4 targets.
- 203 Following the aforementioned principles, we identified a primary target (HCG18) and multiple
- secondary targets associated with MN. Moreover, we identified four primary targets (AFF3,
- 205 CYP21A2, DPH3, HLA-DRB5) and several secondary targets associated with IgAN. Additionally,
- we identified various secondary targets associated with CKD (Table 1). In the case of MN, a decrease

- of 1 standard deviation (SD) in HCG18 expression was significantly associated with an 82% 207
- reduction in risk (OR: 0.18, 95% CI: 0.08-0.43, $P^{SMR} = 9.79 \times 10^{-5}$). Regarding IgAN, an increase of 1 208
- SD in AFF3 expression was linked to a 46% reduced risk (OR: 0.54, 95% CI: 0.39-0.74, $P^{SMR} =$ 209
- 1.64×10^{-4}). Similarly, an increase of 1 SD in CYP21A2 expression was associated with a 42% reduced risk (OR: 0.58, 95% CI: 0.45-0.76, P^{SMR} = 5.53×10^{-5}), an increase of 1 SD in DPH3 210
- 211
- expression was correlated with a 27% reduced risk (OR: 0.73, 95% CI: 0.66-0.80, $P^{SMR} = 3.89 \times 10^{-10}$ 212
- ¹¹), and an increase of 1 SD in HLA-DRB5 expression was linked to a 26% reduced risk (OR: 0.74, 213
- 95% CI: 0.43-0.86, $P^{SMR} = 8.54 \times 10^{-5}$). The reverse TSMR analysis revealed an inverse relationship 214
- between IgAN and only HLA-DPA1, HVCN1, and EHMT2, while no associations were found for 215
- 216 the remaining targets in kidney diseases.

217 3.1 **Phewas**

218 Through comprehensive phenotypic Mendelian randomization, we uncovered a range of diseases and

219 phenotypes associated with kidney disease. These diseases and phenotypes may exhibit comorbidity

220 with kidney disease. Moreover, employing a two-step approach, we identified diabetes, lipid

221 metabolism, and other factors as potential pivotal mediators that influence kidney disease via genetic

222 pathways.

223 3.2 **Functional Enrichment Analysis**

224 Pathways associated with key genes were identified through functional enrichment analysis. The

- 225 AKT gene, CD4-positive dendritic cells, the immunoreceptor signaling pathway (UPG0:0002429),
- 226 SATO-mediated methylation-induced silencing in pancreatic cancer, KRIGE's response to
- 227 TOSEDOSTAT after 24 hours, and the carboxylic acid metabolism process may be associated with
- 228 MN through key genes. Th17 cell differentiation and lipid metabolism may be associated with IgAN
- 229 through key genes. Differences or upregulation between TARTE cells, plasma cells, and plasmablasts
- 230 under specific conditions or treatments may be associated with CKD.

231 4 Discussion

232 To the best of our knowledge, this study represents the pioneering attempt to integrate blood

- 233 genomics data with SMR, TSMR, Bayesian colocalization, phenotype scanning, KEGG, GO pathway
- 234 analysis, and PPI analysis methods. Multiple databases were utilized to uncover and validate the
- 235 potential roles of specific genes in MN, IgAN, and CKD. Through genetic prediction, we established
- 236 a causal relationship between HCG18 and MN, AFF3, CYP21A2, DPH3, HLA-DRB5 and IgAN,
- 237 and HLA-DQB1-AS1 and CKD (the highest-level targets discovered for each disease are listed here).
- 238 After conducting a series of analyses, we ultimately identified the aforementioned genes as high-
- 239 priority potential drug targets for kidney diseases. According to the target principles mentioned
- 240 earlier, we believe these genes can function as potential drug targets for the treatment of kidney
- 241 diseases, and several of them are druggable.
- 242 By utilizing SMR and employing various validation methods, we have newly identified several
- 243 promising genes, thus enhancing their potential as therapeutic intervention targets. Therefore, to
- 244 determine innovative targets for drug interventions in kidney diseases, we conducted comprehensive
- 245 analyses to assess the causal relationships of genes. Causal relationships identified through MR may
- 246 involve reverse causality, horizontal pleiotropy, or genetic confounding induced by LD. Therefore, in
- 247 this study, we employed IVs exhibiting strong correlations with the genes, utilized the HEIDI test to
- 248 estimate LD, and excluded IVs that exhibited evidence of linkage disequilibrium during MR
- 249 implementation. Reverse Mendelian randomization analysis uncovered bidirectional causal

- 250 relationships between HLA-DPA1, HVCN1, EHMT2, and IgAN. Additionally, Bayesian
- colocalization was utilized to mitigate bias introduced by LD (24). Employing a posterior probability
- threshold of 0.5, it was deemed to possess moderate to high colocalization strength, and we identified all genes that exhibited SMR positivity. Nevertheless, these associations alone do not fully elucidate
- all genes that exhibited SMR positivity. Nevertheless, these associations alone do not fully elucida the connections between the identified genes and kidney diseases. Additionally, we performed
- the connections between the identified genes and kidney diseases. Additionally, we performed phenotype scanning analyses of the instrumental variables utilized in the MR analysis to address
- confounding factors. Thus, the aforementioned genes have the potential to serve as drug targets for
- 257 kidney diseases, with a particular focus on Tier 1 targets.
- 258 Membranous Nephropathy
- 259 HLA Complex Group 18 (HCG18) is a long non-coding RNA gene. For HCG18 and MN, there are
- some indications of a potential relationship, although it is not well-established. Research has shown
- that long non-coding RNAs (lncRNAs), including HCG18, are involved in various biological
- processes and diseases, including cancer, COVID-19 infections, and potentially other complex
- 263 conditions like nephropathy(20–22). However, specific studies directly linking HCG18 to MN are
- sparse. One study suggests that lncRNAs like HCG18 could regulate immune responses and cellular
- 265 processes that might be relevant to diseases like MN, but conclusive evidence is lacking.
- 266 IgA nephropathy
- 267 AFF3, also known as ALF Transcription Elongation Factor 3, is a protein-coding gene that encodes a
- 268 nuclear transcriptional activation factor with tissue-restricted expression, primarily in lymphoid
- tissues. AFF3 is associated with diseases such as Familial Syndrome and Intellectual Developmental
- Disorder, specifically X-linked 109. Furthermore, it is suggested that this gene may contribute to
- 271 lymphoid development and tumor formation. CYP21A2, also known as Cytochrome P450 Family 21
- Subfamily A Member 2, is a protein-coding gene. CYP21A2 is associated with diseases such as
- Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency and Classical Congenital Adrenal
 Hyperplasia, both caused by 21-hydroxylase deficiency. HLA-DRB5, a member of the Major
- Hyperplasia, both caused by 21-hydroxylase deficiency. HLA-DRB5, a member of the Major
 Histocompatibility Complex Class II, is a protein-coding gene that encodes the DR Beta 5 subunit.
- 275 Histocompatibility Complex Class II, is a protein-coding gene that encodes the DK Beta 5 subunit.
 276 HLA-DRB5 is associated with diseases such as Pityriasis Rosea and Systemic Lupus Erythematosus.
- 112A-DRD5 is associated with diseases such as Fityhasis Rosea and Systemic Eupus Erymematosu 277 It involves related pathways, including TCR Signaling and Phosphorylation of CD3 and TCR zeta
- chains. DPH3, also called Diphthamide Biosynthesis 3, is a protein-coding gene. DPH3 is associated
- with diseases such as Diphtheria and Melanotic Schwannoma. It involves related pathways such as
- 280 Protein Metabolism, γ -carboxylation, hypusine formation, and arylsulfatase activation.
- 281 Chronic Kidney Disease
- HLA-DQB1-AS1, an RNA gene classified as a long non-coding RNA (lncRNA), It has been
- suggested to be associated with Osteoarthritis and Muscle Atrophy.
- Our study has several limitations. Firstly, the blood genomic data used in our analysis were sourced
- from two distinct studies that may have utilized varying measurement standards. However, we chose
- a database with a large sample size as the discovery cohort, and another one as the validation cohort.
- 287 Secondly, during the validation process using different databases, certain genes did not produce
- results, resulting in missing data. Missing data does not imply insignificant findings; instead, it
- signifies unknown information. Thirdly, the data utilized in our experiments solely represent the European population, necessitating further research to extend the generalizability of our findings to
- European population, necessitating further research to extend the generalizability of our findings to other ethnicities. Additionally, the precise mechanisms underlying these genes and kidney diseases
- are still unknown. It is essential to acknowledge that unvalidated data analysis may encompass

- aspects necessitating experimental verification, thereby enabling the achievement of objectives
- beyond the scope of data analysis alone. Our data can be utilized in future research to validate drug
- targets. Enhancing our comprehension of the genetic regulation of drug targets and the circulating
- 296 levels of biomarkers may improve drug interventions and clinical trials.

297 **5 Data availability**

- eQTLs data was derived via public research(23), and MN data was retrieved from Kiryluk Lab(16).
- 299 We used R language version 4.3.0 for our analysis. In R language, we utilized the "coloc
- 300 (https://github.com/chr1swallace/coloc.git)" and "TwoSampleMR
- 301 (https://github.com/MRCIEU/TwoSampleMR.git)" and "locuscompare" packages for our
- analysis(24).

303 6 Conflict of Interest

- 304 The authors declare that the research was conducted without any commercial or financial 305 relationships that could potentially create a conflict of interest.

306 7 Ethic

- 307 The data utilized in this analysis were obtained from publicly accessible databases. All of the data
- 308 have been de-identified and received ethical approval from the appropriate ethics committee.
- 309 Consequently, this study does not necessitate individual ethical approval.

310 8 Author Contributions

Zhihang Su and Qijun Wan jointly accomplished all efforts. Rui Xue, Jiaqi Liu, Liling Wu, and Yuan
 Cheng contributed to revising and refining the article.

313 **9 Funding**

314 Shenzhen Key Medical Discipline Construction Fund (SZXK009) and SZSM202211013.

315 10 Acknowledgments

316 Sincere thanks to all participants who participated in producing the public database.

317 11 References

- Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2017 Jun 7;12(6):983–97.
- Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, et al. IgA nephropathy. Nat Rev
 Dis Primer. 2023 Nov 30;9(1):67.
- 322 3. Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015 Jun 2;162(11):ITC1-16.
- Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014 Sep 15;23(R1):R89-98.

- Sekula P, Del Greco M F, Pattaro C, Köttgen A. Mendelian Randomization as an Approach to
 Assess Causality Using Observational Data. J Am Soc Nephrol JASN. 2016 Nov;27(11):3253–
 65.
- Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. Res Synth
 Methods. 2019 Dec;10(4):486–96.
- 330
 7. Su Z, Wan Q. Potential therapeutic targets for Membranous Nephropathy: proteome-wide
 331
 Mendelian randomization and colocalization analysis. Front Immunol. 2024 Feb 21;15:1342912.
- Buan QQ, Wang H, Su WM, Gu XJ, Shen XF, Jiang Z, et al. TBK1, a prioritized drug
 repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian
 randomization and pharmacological verification in vitro. BMC Med. 2024 Mar 5;22(1):96.
- Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian
 Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019 Mar
 14;380(11):1033–42.
- 10. Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, et al. Causal effects
 of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis.
 Am J Hum Genet. 2014 Feb 6;94(2):198–208.
- 11. Yuan S, Xu F, Li X, Chen J, Zheng J, Mantzoros CS, et al. Plasma proteins and onset of type 2
 diabetes and diabetic complications: Proteome-wide Mendelian randomization and colocalization
 analyses. Cell Rep Med. 2023 Sep 19;4(9):101174.
- Yuan S, Larsson SC. Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux
 disease: a Mendelian randomization study. Eur J Epidemiol. 2022 Jul;37(7):747–54.
- 346 13. Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al. Integration of the
 347 Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res.
 348 2021 Jan 8;49(D1):D1144–51.
- 349 14. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome
 and support for target identification and validation in drug development. Sci Transl Med. 2017
 351 Mar 29;9(383):eaag1166.
- 15. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and
 trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood
 gene expression. Nat Genet. 2021 Sep;53(9):1300–10.
- 355 16. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al. The genetic architecture of membranous
 appropathy and its potential to improve non-invasive diagnosis. Nat Commun. 2020 Mar
 357 30;11(1):1600.
- 17. Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, et al. Genome-wide
 association analyses define pathogenic signaling pathways and prioritize drug targets for IgA
 nephropathy. Nat Genet. 2023 Jul;55(7):1091–105.

- 18. Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, et al. Genetic associations at 53
 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun.
 2016 Jan 21;7:10023.
- Köttgen A, Pattaro C. The CKDGen Consortium: ten years of insights into the genetic basis of
 kidney function. Kidney Int. 2020 Feb;97(2):236–42.
- 20. Yuan Z, Zhang Y, Chen P, Liu S, Xin L, Liu C. Long non-coding RNA HLA complex group 18
 promotes gastric cancer progression by targeting microRNA-370-3p expression. J Pharm
 Pharmacol. 2022 Feb 1;74(2):250–8.
- Chang M, Gao H, Li Y, Ding C, Lu Z, Li D, et al. Identification and analysis of MSC-Exo derived LncRNAs related to the regulation of EMT in hypospadias. BMC Med Genomics. 2024
 Apr 16;17(1):87.
- 372 22. Greco S, Made' A, Mutoli M, Zhang L, Piella SN, Vausort M, et al. HCG18, LEF1AS1 and
 373 IncCEACAM21 as biomarkers of disease severity in the peripheral blood mononuclear cells of
 374 COVID-19 patients. J Transl Med. 2023 Oct 26;21(1):758.
- 23. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide
 Mendelian randomization mapping the influence of the plasma proteome on complex diseases.
 Nat Genet. 2020 Oct;52(10):1122–31.
- 24. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations with gene
 expression complicate GWAS follow-up. Nat Genet. 2019 May;51(5):768–9.
- 380

381 **12 Figure legends**

382 Figure 1: Study design.

MN: membranous nephropathy; IgAN: IgA nephropathy; CKD: chronic kidney disease; HEIDI
 test: heterogeneity in dependent instruments; FDR: false discovery rate; PPH4: posterior probabilities
 of hypotheses 4.

386

